These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6820039)

  • 41. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine].
    Schiller B; Lysakowska E; Owczarska K
    Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849
    [No Abstract]   [Full Text] [Related]  

  • 42. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
    Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
    Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
    [No Abstract]   [Full Text] [Related]  

  • 43. [Morphological study of the organs and tissues of mice infected after a burn with a Pseudomonas aeruginosa strain and treated with a Pseudomonas aeruginosa polyvalent corpuscular vaccine and tobramycin].
    Moroz AF; Kharitonova AM; Chanturiia TsK
    Antibiotiki; 1983 May; 28(5):341-5. PubMed ID: 6410985
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis.
    Zuercher AW; Horn MP; Que JU; Ruedeberg A; Schoeni MH; Schaad UB; Marcus P; Lang AB
    FEMS Immunol Med Microbiol; 2006 Jul; 47(2):302-8. PubMed ID: 16831219
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current status of Pseudomonas aeruginosa vaccine.
    Michelim L; Medeiros GS; Zavascki AP
    Curr Pharm Biotechnol; 2013; 14(11):951-9. PubMed ID: 24372247
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthetic peptide vaccine and antibody therapeutic development: prevention and treatment of Pseudomonas aeruginosa.
    Cachia PJ; Hodges RS
    Biopolymers; 2003; 71(2):141-68. PubMed ID: 12767116
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of carbenicillin, gentamicin and vaccines on rats experimentally burned and infected with Pseudomonas aeruginosa.
    Toama MA; Hamed IM; Ashour SM
    Pharmazie; 1980; 35(4):228-30. PubMed ID: 6773076
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pseudomonas aeruginosa mucosus strain isolated from a patient with chronic bronchitis and a trial in autoimmunization].
    Okano H; Honma Y; Shionoya H
    Kansenshogaku Zasshi; 1970 Oct; 44(7):380-7. PubMed ID: 4991749
    [No Abstract]   [Full Text] [Related]  

  • 49. [Immunoprophylaxis and immunotherapy of infection caused by Pseudomonas aeruginosa: research results and prospects].
    Stanislavskiĭ ES; Joó I
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Jul; (7):22-31. PubMed ID: 6414198
    [No Abstract]   [Full Text] [Related]  

  • 50. Pseudomonas immunoglobulin and vaccine in burn patients.
    Bose B
    Lancet; 1981 Feb; 1(8217):435. PubMed ID: 6110056
    [No Abstract]   [Full Text] [Related]  

  • 51. [Prophylactic effects of Pseudomonas aeruginosa vaccine on patients with chronic pulmonary disease].
    Tateda K; Yamaguchi K
    Nihon Rinsho; 1991 Oct; 49(10):2416-20. PubMed ID: 1749098
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection.
    Okada K; Kawaharajo K; Kasai T; Homma JY
    Jpn J Exp Med; 1980 Feb; 50(1):53-61. PubMed ID: 6770131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pseudomonas aeruginosa. Vaccines and immunotherapy.
    Pennington JE
    Infect Dis Clin North Am; 1990 Jun; 4(2):259-70. PubMed ID: 2111838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vaccines and immunotherapy against Pseudomonas aeruginosa.
    Döring G; Pier GB
    Vaccine; 2008 Feb; 26(8):1011-24. PubMed ID: 18242792
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Passive immunotherapy for treatment of endobronchitis in cystic fibrosis].
    Moss RB
    Infusionsther Transfusionsmed; 1993 Apr; 20 Suppl 1():42-6; discussion 47. PubMed ID: 8499750
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preliminary investigations of Pseudomonas aeruginosa vaccine in patients with leukemia and cystic fibrosis.
    Pennington JE
    J Infect Dis; 1974 Nov; 130 Suppl(0):S159-62. PubMed ID: 4213986
    [No Abstract]   [Full Text] [Related]  

  • 57. [Effectiveness of a polyvalent corpuscular Pseudomonas aeruginosa vaccine, antibiotics and their combinations in experimental chronic Pseudomonas aeruginosa infection].
    Vetkova LG; Antsiferova NG; Radkevich SA; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Mar; (3):51-6. PubMed ID: 3922187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of immunotherapy for infections due to Pseudomonas aeruginosa.
    Fisher MW
    J Infect Dis; 1974 Nov; 130 Suppl(0):S149-51. PubMed ID: 4138585
    [No Abstract]   [Full Text] [Related]  

  • 59. [Immunomodulation in Pseudomonas urinary infection].
    Urban M; Tamele L
    Rozhl Chir; 1995 Nov; 74(7):319-21. PubMed ID: 8629153
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Experimental basis for the combined use of tobramycin and immune preparations for treating acute Pseudomonas aeruginosa infections].
    Minukhin VV; Tsyganenko VIa
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Aug; (8):42-5. PubMed ID: 3094301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.